EuroSciCon invites participants from all over the world to attend ''17th Edition of International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems” during October 04-06, 2018 at Moscow, Russia which includes prompt keynote presentations, Oral talks (Speaker Forum and Young Research Forum), Poster presentations, Symposium, Workshops and Exhibitions.
Pharmaceutics 2018 spreads an extensive range of critically important sessions from basic research to recent innovations. The theme: “Challenges Innovations and Advances in Novel Drug Delivery Systems” is designed for professionals at all levels and career phases of the Pharma industry, who want to improve their understanding of what will drive and shape the future of the market.
Pharmaceutics deals with the process of turning a new chemical entity (NCE) into a medication to be used safely and effectively by patients. Pharmaceutics helps relate the formulation of drugs to their delivery and disposition in the body. Global pharmaceutical industry completely relies on research and development to expand its offerings among consumers. Continuous development of drug compounds, discovery of new ones, and establishment of most effective routes for drug delivery after intensive clinical trials are crucial. The Pharmaceutical industry is directly impacted by the research conducted with prescription drugs, vaccines, and OTC drugs being manufactured. The global pharmaceutical market is expected to surpass US$400 bn by 2018, with the ten largest pharmaceutical companies collectively commanding about a third of the market. The development of biopharmaceuticals represents a milestone for the industry and personalized therapies carry immense promise in the near future. A recent analysis by QuintilesIMS projects that the global pharmaceutical industry will grow at a compound annual rate of 4% to 7% during the next five years, down from the nearly 9% growth level seen in 2014 and 2015
The global active pharmaceutical ingredients market is expected to reach USD 213.97 Billion by 2021 from USD 157.95 Billion in 2016, growing at a CAGR of 6.3% from 2016 to 2021. The global pharmaceutical excipients market is projected to reach USD 8.1 Billion in 2021 at a CAGR of 6.1% in the forecast period 2016 to 2021.
The global market for over the counter (OTC) drugs and dietary supplements reached $164.7 billion in 2016 and should reach $220.8 billion in 2021, with a compound annual growth rate (CAGR) of 6.0%.The global market for generic drugs should reach $533 billion by 2021 from $352 billion in 2016 at a compound annual growth rate (CAGR) of 8.7%, from 2016 to 2021.
Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. Current efforts in the area of drug delivery include the development of targeted delivery, sustained release formulations and methods to increase survival of peroral agents which must pass through the stomach's acidic environment. Drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period.
Why to attend our Conference:
Euroscicon Conferences promotes the positive contributions of Pharmaceutics. Highlighting the material’s beneficial properties and its positive contributions to society throughout its life cycle providing society with educational information to help raise awareness and correct misconceptions. Discover how advances in the sector are impacting both large and small molecule drugs.Explore new routes to improve bioavailability. Liaising with European and national institutions in policy matters to secure decisions based on accurate information.Communicating chemicals and its related contribution to sustainable development, innovation and quality of life initiating in depth studies and sharing experiences.Understand how to develop the right formulation and delivery strategy with a strong scientific, clinical and commercial mind set. Discover the latest innovations in drug delivery devices.Get to know why formulation and delivery strategies fail. Dissect the challenges before looking for concrete solutions. Share experiences, insights and strategies in interactive peer-to peer round tables. Discover how scientific formulation advancements are being implemented in practice.
Preformulationstudies are an essential aspect for various phases of clinical trials. Preformulation studies act as the preliminary step as well as the scientific foundation for formulation design and development.These studies provide guidance in selection of drug, excipients,to determine chemicalcomposition, physical pattern and assist in adjustment of pharmacokinetic profiles. Improving public safety measures and intensifying product quality are the other characteristics.
The main purpose of preformulation studies is to enhance compatibility with the other ingredients and develop elegant, stable, potent and safe dosage form. Physico-chemical parameters, drug solubility studies, partitioncoefficient,dissolution kinetics, polymorphism and stability profiles play a significant role in preformulation studies.These studies furnish the information regarding the degradation process, toxic effects and adverse conditions. So Preformulation is an interdisciplinary basis in drug development.
The task of preformulation and optimization process became comfortable with the support of statistical software based on artificial neural networking. Past perspectives, Present Scenario and Future opportunities will be addressed in this Preformulation conference.
Track 2: Pharmaceutical Formulations
Formulation is defined as the method in which different chemical substances including the main activeingredient are compounded to produce a final dosage form. Developed formulations should be stable, safe and acceptable to the patient.
Global Contract Pharmaceutical manufacturing market is estimated to reach $94.63 billion by 2022 from $65.55 billion in 2016, at a CAGR of 6.31% for 2016 to 2022 period. North America holds major share in Global Contract Pharmaceutical manufacturing market.Asia-Pacific especially India-is the fastest growing market. The main countries operating in this industry are US, Canada, China, India, Japan and Australia.
Track 3: Routes of Drug Administration
The route of administration is the path through which the dosage form (active substance) is administered into the body for treatment of various diseases and disorders. Routes of administration are classified based on 1.the location at which the dosage form is applied 2. Target of action. These include oral, topical and enteral (system-wide effect, but delivered through the gastrointestinal tract), or parenteral (systemic action, but delivered by routes other than the GI tract).
Taking them correctly and understanding the right way to administer can reduce the risks. The route used to administer a drug depends on three main factors: 1. the part of the body being treated 2.the way the drug works within the body 3.the formula of the drug. These routes enhance the bio availability of drug molecule.
The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. This market analysis is based on route of administration, facility of use.
The topical drug delivery market is expected to reach USD 125.88 Billion by 2021 from USD 92.40 Billion in 2016 at a CAGR of 6.4% from 2016 to 2021 forecast period.
The oral drug delivery market was valued at $49 billion in 2010, and is forecast to grow at a CAGR of 10.3% until reaching $97 billion by 2017.
Pharmacokinetics describes how the medicament gets influenced after administration, followed by absorption, distribution, metabolism mechanisms and excretion of the drug substance. Pharmacokinetic knowledge assist prescribers to adjust dosage more accurately and precisely. Clinical kinetics is defined as the applications of pharmacokinetic principles in the safe and adequate management of individual patient. Toxic pharmacokinetics is defined as the applications of pharmacokinetic principles to the design, behaviour and interpretation of drug safety evaluation studies.
Pharmacodynamics describes biochemical, physiological, and molecular effects of drugs on the body and involves receptor binding (including receptor sensitivity), post receptor effects, and chemical reactions. The pharmacologic response depends on the drug binding to its target. Pharmacodynamics is defined as the relationship between drug concentration at the site of action and the resulting effect. The effect of a drug present at the site of action is measured by drug-receptor binding.
Drug delivery devices are employed to inject drugs in the body through a particular route of administration, which in turn depends on the type of disease, desired action, and available products. These devices enhance the efficiency of the drug delivery system by controlling time, dosage, and site of release of the drugs in the body. Target specificity, dose-optimization and high level of safety and efficiency are the characteristics of these devices. Devices may be conventional or implantable.
Rising geriatric population, technological advances, and increasing demand for improved drug delivery systems are the key tools driving the growth of the global drug delivery devices market.
The Global Drug Delivery Devices Market accounted to USD 1,027.0 billion in 2016 growing at a CAGR of 8.1% during the forecast period of 2017 to 2024.
Europe Drug Delivery Market expected to reach USD 536.1 billion by 2024 from USD 305.5 billion in 2016, at a CAGR of 7.3% in the forecast period 2017 to 2024.
Some of the major companies in Drug Delivery Devices market are 3M Company, Merck & Co., Inc., Pfizer Inc., Johnson & Johnson, Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Abbott, Novartis AG, Valeant Pharmaceuticals International, Inc., Mylan Pharmaceuticals Inc., Antares Pharma.
Drug delivery is the action of administering a pharmaceutical drug into the body for a therapeutic effect through various routes. Drug delivery technologies modify drug release profiles, pharmacokinetic parameters for the benefit of improving product efficacy and safety, as well as patient convenience and compliance. Conventional routes cannot deliver compounds such as proteins, antibodies, vaccine and gene based drugs because these routes are susceptible to enzymatic degradation or cannot be absorbed into the systemic circulation efficiently due to large molecular size and charge issues.
Technologies include digitally controlled needle-free devices, sustained and controlled transdermal delivery technology, fiber-based technology for implantable devices, targeted penetration matrix technology for non-invasive delivery and location-specific nano devices for chemotherapy delivery. Many innovative technologies for effective drug delivery have been developed, including implants, nanotechnology, cell and peptide encapsulation, micro fabrication, chemical modification.
Biotechnology advances are leading to develop medications that can target diseases more effectively and precisely. If a drug is more targeted, the chance of triggering drug resistance is lower, a cautionary concern surrounding the use of broad-spectrum antibiotics.
Nanotechnology delivers drugs to targeted cells using nanoparticles. The overall drug consumption and side-effects are lowered significantly by depositing the active drug in the particular site and preventing administration of booster doses. Nanotechnology based devices are less invasive, can be safely implanted inside the body and biochemical reaction times are much shorter.
Track 7: Nanotechnology in Drug Delivery
Nanotechnology became the driving force behind various evolutionary and revolutionary changes in the scientific field. Nanotechnology drug delivery enhanced the efficacy of available medicaments and enabled to create entirely new medical products. Nanotechnology has opened the door to new approaches to stimulate the reconstruction of complex tissue structures. Nanoparticles are used to deliver the drug to the specific diseased cell where particles attract to the diseased cell and provide treatment. By this unique technique, we can minimize the damage of healthy cells in the body.
Nanotechnology-dependent detectors e.g. nanowires, nanotubes, nanoparticles, cantilevers, and nano arrays consume low sample and enhance fast detection of disease. Target based Nano probes (e.g. magnetic nanoparticles, quantum dots, and carbon nanotubes) provide a faster, less invasive, and more accurate way for early diagnose of diseases. Reporting in vivo efficacy of therapeutics and helping surgeons to locate tumors are other opportunities of nanotechnology.
Some nanotechnology-based drugs that are commercially available are- Abraxane, approved by the U.S. Food & Drug Administration (FDA) to treat breast cancer. Doxil was approved by the FDA for the treatment of ovarian cancer.
The global nanotechnology drug delivery market was valued at US$ 41,062.5 Mn in 2014 and is projected to reach US$ 118,527.2 Mn by 2023, expanding at a CAGR of 12.5% from 2015 to 2023.
Key players having presence in the global nanotechnology drug delivery market are AbbVie, Inc., Amgen, Inc., Celgene Corporation, Johnson & Johnson, Merck & Co., Inc., and Novartis International AG, among others.
Targeted drug delivery is a kind of smart drug delivery, a method of delivering medication to a patient in a manner that increases the concentration only in particular part of the body. The goal of a targeted drug delivery system is to prolong, localize and have a protected drug interaction with the diseased tissue. The advantages of the targeted drug delivery are 1. reduction in the frequency of the dosages taken by the patient 2. have a more uniform effect of the drug, 3.reduction of drug side-effects 4. reduce fluctuation in circulating drug levels 5.maintain the required plasma and tissue drug levels in the body. In chemotherapy only a small portion of the medication reaches the affected organ and roughly 99% of the administered drug does not reach the tumor site.
While designing a targeted drug delivery, the following criteria must be taken into consideration: the drug properties, the route of drug delivery, the targeted site, disease and the side effects of drug. There are two kinds of targeted drug delivery: active targeted drug delivery, such as antibody medications, and passive targeted drug delivery, such as the enhanced permeability and retention effect.
Track 9: Drug Delivery Vechiles
A drug carrier improves the selectivity, effectiveness, and safety of drug administration. Drug carriers are primarily used to control the release of a drug into systemic circulation. This can be accomplished either by slow release of the drug over a long period of time (typically diffusion) or by triggered release at the drug's target by stimulus, such as changes in pH, application of heat, and activation by light. Drug carriers improve the bioavailability of poorly water soluble or membrane permeable drugs.
An ideal drug delivery vehicle must be non-toxic, biocompatible, non-immunogenic, biodegradable and must avoid recognition by the host's defense mechanisms. Different methods of drug attachment to the carrier include adsorption, integration into the bulk structure, encapsulation, and covalent bonding. As many drug delivery carriers are involved in delivery of the drug, the conference can be re-named as Drug Delivery carrier conference.
Track 10: Drug Delivery through BBB
One of the biggest challenges in the drug development for central nervous system (CNS) disorders is achieving significant blood–brain barrier (BBB) penetration.
Several drugs do not have high lipid solubility, low molecular size and positive charge to traverse BBB. The problems associated with the blood–brain barrier are1. The drug produced allows only a small amount to pass through the barrier 2. Binding to other proteins in the body renders the drug ineffective or pass through the barrier with the adhered protein. 3. The presence of enzymes in the brain that could render the drug inactive. All of these problems must be addressed and accounted to deliver effective drugs to the brain.
Nano biotechnology-based delivery methods provide the best approach to deliver drugs. Several developed strategies, enhance the capacity of drug molecules to cross the BBB by modifying the drug or by coupling it to a vector for receptor-mediated or adsorption-mediated transcytosis.
By 2019, compounds using BBB technology in the clinical development would reach approximately eight. The global market for BBB technologies was valued at $38.7 million in 2014. The market is expected to grow to $471.5 million by 2019, and register a tremendous 64.9% CAGR from 2014 through 2019.
Track 11: Protein, Peptide and Gene Drug Delivery
Peptides and proteins have great potential as drug delivery. Compared with the small size drugs, peptides and proteins can be highly selective as they have multiple points of contact with their target. Increased selectivity also result in decreased side effects and toxicity. Peptides can be designed to target a broad range of molecules and provide opportunities in oncology, immunology, infectious disease and endocrinology. The market for peptide and protein drugs is estimated to be greater than US$40 billion/year, or 10% of the pharmaceutical market .At present there are over 100 approved peptide-based drugs in the market. The pharmaceutical scientists have approaches to develop the protein and peptide delivery formulations by noninvasive routes.
Gene therapy is defined as incorporation of genetic material i.e, DNA or RNA, in the cellular gene regulation system, either to correct the expression of a malfunctioning gene or to modulate the cellular functions. Nanotechnology advancements have given rise to the development of nanoparticle-DNA delivery systems. Gene delivery is an integral part of genome evolution. Gene delivery utilizes non-immunogenic vectors capable of cell specificity that can deliver an adequate amount of transgene expression to cause the desired effect. Advances in gene therapy have enabled a variety of new methods and gene targets to be identified for possible applications. Gene delivery has been utilized to generate a hybrid biosynthetic vector to deliver a possible vaccine.
Track 12: Novel Vaccine Delivery Systems
Vaccine is a material that induces an immunologically mediated resistance to a disease but not necessarily an infection. Vaccines are generally composed of killed or attenuated organisms or subunits of organisms or DNA encoding antigenic proteins of pathogens. Vaccines though exceptionally selective and specific in reacting with antibodies often fail to show reactions in circumstances such as shifts in epitopic identification center of antibody and are poorly immunogenic. These vaccines require boosting with agents called adjuvants in order to induce an effective immunity. Adjuvants potentiate the immunostimulatory property of the antigen and are non-immunogenic, nontoxic, and biodegradable in nature.
Conventional immunization regimen involves prime doses and booster doses. Immunization failed as patients neglect the booster doses. These reasons necessitated the development of new generation of prophylactic and therapeutic vaccines to promote effective immunization. Vaccines allow for the incorporation of doses of antigens so that booster doses are no longer necessary as antigens are released slowly in a controlled manner. Attempts are being made to deliver vaccines through carriers as they control the spatial and temporal presentation of antigens to immune system thus leading to their sustained release and accurate targeting. Carrier systems such as liposomes, microspheres, nanoparticles, dendrimers, micellar systems, ISCOMs, plant-derived viruses are being investigated and developed as vaccine delivery systems.
Track 13: Smart Materials for Drug Delivery
Materials are called “smart” when these materials have the ability to respond to stimuli and have high potential in novel drug delivery systems. The delivery of drugs to specific locations in the human body using smart materials has been approaching the forefront place in research for the past few decades. Materials for delivering drugs must design drug carriers that do not interact non-specifically within the body.
Polymers have played an important role in the advancement of drug delivery technology by providing controlled release of therapeutic agents in constant doses over long periods and release of both hydrophilic and hydrophobic drugs. The greatest advantage of polymers is their ability to chemical modification, resulting in defined chemical composition, customized surface functionality and the potential for defined three-dimensional structures. Several polymers widely used in clinical therapies are synthetic polymers and natural polymers.
Nanomaterials are used in controlled drug delivery. Drug-delivery systems can be synthesized with controlled composition, shape, size and morphology. Nanoparticles surface properties can be manipulated to increase solubility, immunocompatibility and cellular uptake.
Natural gums are one of the major areas for applications in the drug delivery system because of their wide availability, inexpensiveness.
Track 14: Nanoparticles: Innovations and Trends
Nanoparticles are generally less than 100 nm in dimension and consist of different biodegradable materials such as natural or synthetic polymers, lipids, or metals. Nanoparticles are taken up by cells more efficiently than larger micromolecules. Nanoparticles have high surface area to volume ratio thus allowing many functional groups for attachement. Additionally, the small size of nanoparticles allows them to accumulate at tumor sites.
Nano particles can (1) enhance the therapeutic efficacy and minimize adverse reactions associated with available drugs; (2) enable new classes of therapeutics; and (3) encourage the re-investigation of pharmaceutically suboptimal but biologically active new molecular entities that were previously considered undevelopable.
Nanoparticles are used in targeted drug delivery to improve the uptake of poorly soluble drugs. Nano particles with different compositions and biological properties have been extensively investigated for drug and gene delivery application.
According to BCC Research the global market for nanoparticles in the life science forecast to grow to more than $79.8 billion by 2019, to register a healthy compound annual growth rate (CAGR) of 22%.
The global nanotechnology market in environmental applications reached $23.4 billion in 2014. This market is expected to reach about $41.8 billion by 2020, registering a compound annual growth rate (CAGR) of 10.2% from 2015 to 2020.
he global market for nanotechnology products was valued at $22.9 billion in 2013 and increased to about $26 billion in 2014. This market is expected to reach about $64.2 billion by 2019, a compound annual growth rate (CAGR) of 19.8% from 2014 to 2019.
Track 15: Herbal Novel Drug Delivery
Novel drug delivery system addresses the limitations of the traditional drug delivery systems. We have a vast knowledge of Ayurveda and the drug delivery system used for administering the herbal medicine to the patient is traditional. So it is important to integrate novel drug delivery system and Indian Ayurvedic medicines to combat serious diseases.
Reasons for using herbal medicines are 1. Growing concern over the reliance and safety of drugs 2.Failure of modern medicine to treat most common health conditions 3. Natural medicines are producing better results without side effects.
Novel herbal formulations like polymeric herbal Nano-carriers, phytosomes, herbosomes, pro-niosomes, Nano emulsions, microsphere, transferosomes, implants and ethosomes has been reported using bioactive plant extracts. Advantages include Solubility, bioavailability enhancements, reduced toxicity, improved pharmacological activity, sustained delivery, and protection from physical and chemical degradation. Many formulations are produced from various herbal drugs such as curcumin, quercetin, silybin, bilobalide, marsupsin, andrographolide.
According to WHO because of poverty and lack of access to modern medicine as well as self-belief, about 65-80% of the world's population living in developing and developed countries depends on plants for primary health.
Track 16: Drug Discovery and Development Obstacles
In spite of discovery of various drugs, several challenges are unmet and there is always a need to compensate our resources in fighting to solve issues at a basic science level and also for the development of new drugs, new approaches for treatment. There is always a quest for new knowledge that is available today for any specific medical condition. There are several unknown solutions thus finding a novel drug for a disease is always a challenge. Following the path from discovery of a molecule through the road of development is complex and involves time, money and multiple disciplines to move it ahead.
Despite efforts to hasten the process of drug development using innovative technologies, the current efforts still appear to be ineffective. Several novel strategies like academia-industry interactions that foster a conversion of novel technologies to product and public – private funding have not helped to conquer several diseases Therefore, it becomes important to identify the areas in the development chain that needs to be improved by which one can hasten the process.
Pharmaceutical industry and drug discovery research applied all the basic scientific data and have developed procedures and guidelines that enable the conversion of information into useful tools that can be used to treat disease. But the curve of submissions of new drugs and biologics to FDA is in the opposite direction, a mirror image of the investment curve. The major concern is related mainly to the costs of preclinical and clinical trials studies. Reasons for submission curve are the industry's lower revenue growth, poor stock performance, the lowest number of new chemical entity (NCE) approvals and the poor late-stage R&D which is prevalent throughout the industry.
Track 17: Drug Delivery: Facing Challenges
Innovative, non-invasive delivery include drivers like improvement of patient acceptability and compliance ,improvement in public safety, decrease of administration costs and a reduction of adverse effects. Enzyme degradation, acid degradation, hydrolysis and low permeability of intestinal epithelium in the gastrointestinal (GI) tract surfaces make oral administration a non-viable delivery method. Conventionally, many drugs such as proteins are administered parenterally since oral administration cause low bioavailability in the GI tract. It has become a challenge to achieve consistent and adequate bioavailability levels for oral administration.
Economic and financial barriers also stand in the way of implementing nano medicine. The limited availability of reimbursement by public and private health insurers for expensive new diagnostic tests has emerged as a major impediment to the deployment of personalized medicine. Nanoproducts encounter even greater hurdles because of their costs and complexity, cytotoxicity of nanoparticles are main concern of future research.
Advances in medical science, research and development (R&D) are changing the dynamics of the life science industry, including pharmaceuticals and healthcare. The development of new drugs necessitates the development of different drug delivery systems, which is further driven by innovation in technology, R&D and scientific advancements. Advances in understanding human biology, diseases and medical treatments are opening new opportunities in the pharmaceutical industry. A drug delivery system is an important area where the need for better technologies for drug administration or delivery is in demand
Activities have been increased regarding the development and research on various printing techniques in fabrication of dosage forms. These technologies offer flexibility in manufacturing, potentially pave the way for personalized dosing and tailor-made dosage forms.
Drug delivery from 3-dimensional (3D) structures is a rapidly growing area of research. 3DP can fabricate solid dosage forms with variable densities and diffusivities, complex internal geometries, multiple drugs and excipients.
3DP uses computer aided technology and programme to transform 3D computer aided designs (CAD) into life-changing products. These design more effective and patient-friendly pharmaceutical products as well as bio-inspired medical devices. Levetiracetam (SPRITAM®) tablet a pharmaceutical product is developed by using 3DP technology.
3DP offers advantages like (a) high production rates due to its fast operating systems, (b) ability to achieve high drug-loading with much desired precision and accuracy especially for potent drugs that are applied in small doses, (c) reduction of material wastage which can save in the cost of production and (d) amenability to broad types of pharmaceutical active ingredients including poorly water-soluble, peptides and proteins, as well as drug with narrow therapeutic windows.
3D structures can be printed on a variety of surfaces with characteristic permeability, porosity, hydrophobicity/hydrophilicity and surface energy. Scientists in collaboration with CAD designers have produced innovative medical devices ranging from pharmaceutical tablets to surgical transplants of the human face and skull, spinal implants, prosthetics, human organs and other biomaterials.
Track 19: Global Drug Delivery Market
The pharmaceutical market in Russia is one of the fastest growing market globally and is set to rise from $20.91 billion in 2016 to $38.56 billion by 2021, representing a compound annual growth rate of 13%, according to GlobalData, Thus, Russia’s pharmaceutical market will almost double to $39billion by 2021.
The medical device market in Russia was valued at $6.7 billion in 2016 and is forecast to reach $8.5 billion in 2021. Major segments likely to experience high growth are ophthalmic devices cardiovascular devices, orthopedic devices.
Drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period.
Prominent players in this market include Johnson & Johnson, Inc., F. Hoffman-La Roche, Merck & Co, Inc. Bayer AG, Pfizer, Inc., Novartis AG, 3M Company, Becton, Dickinson and Company, GlaxoSmithKline plc. Sanoff and Antares Pharma, Inc.
The Global Drug Delivery Technologies Market is poised to grow at a CAGR of around 7.9% over the next decade to reach approximately $2,222 billion by 2025.
North America dominates the global market for injectable drug delivery due to a large aging population and increasing incidences of diabetes. Asia is expected to witness high growth rates in the next five years in the global injectable drug delivery market. China and India are expected to be the fastest-growing injectable drug delivery markets in Asia Pacific.
The global transdermal drug delivery market was valued at $13.5 billion in 2013 and is expected to reach $21.7 billion by 2018, at a CAGR of 11.1% from 2013 to 2018.
An overview of the current global market for drug delivery and formulation enabled and enhanced products provides a sense of what is out there and what we might expect. Drug-Device enhancements over the past few years have generally been incremental and largely predictable in terms of features and performance.
Track 20: Recent Advances in Drug Delivery System
The goal of drug delivery systems is to deliver medications to specific target parts of the body through a medium that can control the therapy’s administration. To achieve this goal, researchers are turning to advances in the worlds of micro- and nanotechnology.
The recent advances in the peptide and protein drug delivery systems are PEGylation and Depo-foam technology. Cell-penetrating peptides (CPPs) act as cargo carriers and constitute a current hotspot in medical research. CPPs to transport hydrophilic macromolecules into cells, thus, assist to execute biological functions. CPPs do not destroy the integrity of the cell membranes, and are considered more efficient and safe and providing new avenues for research and applications in life sciences.
Biologics can be re-engineered for BBB transport with the use of molecular Trojan horse technology.
Needle-free drug delivery systems are novel ways to introduce various medicines to patients. PowderJect Pharmaceuticals one of the first companies to develop a needle-free technology for injecting powdered drugs into the skin. Needle free devices can take the form of power sprays, edible products, inhalers, and skin patches
Organizations such as W.H.O. and C.D.C. (center for disease control) support the development of needle free insulin drug delivery.
Transdermal patches are user-friendly, convenient, painless and offer improved patient compliance.
Nano drug delivery systems such dendrimers, fullerence, nano pores, nanotubes, nano shells, quantum dots, , nanovaccines, revolutionized drug delivery systems. Thus nanomaterial can be used for strategic development of new drug delivery systems and reformulate existing.
Anti-cancer drugs such as loperamide and doxorubicin bound to nanomaterial have been shown to cross the blood-brain barrier.
According to BCC Research the global market for advanced drug delivery systems was valued at $151.3 billion in 2013. This market is forecasted to reach nearly $173.8 billion in 2018, registering a 5-year compound annual growth rate (CAGR) of 2.8%.
The Pharmaceutical industry in Russia had a turnover of $16.5 billion in 2016, which was equal to 1.3 % of GDP and 19.9% of health spending.Russia is a net importer of pharmaceuticals, importing $8.9 billion while exporting $635 million of medicines. Close to 80% of imports come from Europe, mostly from Germany and France.The Russian pharmaceutical market can be divided by prescription drugs and over the counter drugs. The prescription drugs sales historically took the biggest share of the market, capturing 61% of the market in 2016. The sales of generic drugs dominate in the prescription category at 64.5%. Out of all pharmaceutical sales they constitute only 39.4%The Russian government is focused on creating its own pharmaceutical industry. The main document that governs this focus is the “Pharma 2020 Strategy”. Its main goal is to reduce the reliance of the Russian economy on imported pharmaceuticals.
The pharmaceutical industry is one of the most dynamic and complex industries, involving commercialization of cutting-edge scientific research, a huge web of stakeholders ,multi-stage supply chains, fierce competition in the race to market, and a challenging regulatory environment. The stakes are high, with each new product raising the prospect of spectacular success—or failure. Worldwide revenues are approaching $1 trillion; in the U.S. alone, marketing for pharmaceutical products is, itself, a multi-billion dollar industry. Thus pharmaceutical industry as a global sector is inarguable. A global growth rate for the pharma industry of 6.3% CAGR through 2022, up from the 5% CAGR for the 2014-2020 period. During the 2008-2015 period, the compound annual growth rate of global R&D spending was 1.7%; during the 2016-2022 period, the rate will grow at 2.8% Overall spending will reach $182 billion in 2022
The global market for drug discovery technologies reached nearly $39.5 billion and $46.5 billion in 2013 and 2014, respectively. This market is expected to grow at a compound annual growth rate (CAGR) of 11.3% to nearly $79.5 billion for the period 2014-2019. , in order to earn additional margins, the pharmaceutical companies are in pursuit of blockbuster drugs, which has increased the demand for drug discovery technologies. Drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. The global nanotechnology drug delivery market was valued at US$ 41,062.5 Mn in 2014 and is projected to reach US$ 118,527.2 Mn by 2023, expanding at a CAGR of 12.5% from 2015 to 2023.
The global advanced drug delivery market should grow from roughly $178.8 billion in 2015 to nearly $227.3 billion by 2020, with a compound annual growth rate (CAGR) of 4.9%.The North American market should grow from nearly $75.7 billion in 2015 to $93.4 billion by 2020, a CAGR of 4.3%.
The European market should grow from roughly $57.3 billion in 2015 to nearly $72.1 billion by 2020, a CAGR of 4.7%.Asia-Pacific should grow the fastest during the forecast period with a five-year CAGR of 6.4%.
The global advanced drug delivery market is driven by development of new drugs and biologics, advances in understanding human biology and diseases, R & D spending, non-traditional administration routes and new and emerging technologies
Harvard University | University of Cambridge | University of California, San Francisco | University College London | University of North Carolina | Karolinska Institute | Yale University | King's College London | University of California, San Diego | Cardiff University | Stanford University | The Imperial College of Science, Technology and Medicine | The University of Manchester | The University of Texas | Utrecht University | The University of Dundee | Columbia University | Monash University | University of Oxford | Pierre and Marie Curie University | Medical University of Vienna | Rockefeller University | Uppsala University | EuroSciCon Conferences | University of Pennsylvania | University of Zurich | University of Tuebingen | The Ohio State University | Radboud University Nijmegen | Norwegian University of Science and Technology | Vanderbilt University | McGill University | University of Hamburg | University of Lausanne | University of Paris Descartes | The University of Tokyo | University of California, Berkeley | Swiss Federal Institute of Technology Zurich | Kyoto University | University of Wisconsin – Madison | University of Arizona | University of South Florida | University of Utah | China Pharmaceutical University | EuroSciCon
University of Southern California | CUNY York College | Purdue University | University of Wisconsin-Madison | Albany College of Pharmacy and Health Sciences | University of North Carolina | EuroSciCon | University of Colorado | Oregon State University | Nova Southeastern University | Massachusetts College of Pharmacy and Health Sciences | University of Florida College of Pharmacy | University of Michigan College of Pharmacy | Campbell University School of Pharmacy | University of Pittsburgh School of Pharmacy | University of Georgia College of Pharmacy | Temple University School of Pharmacy | Ernest Mario School of Pharmacy | Skaggs School of Pharmacy | Eugene Applebaum College of Pharmacy and Health Sciences | University of North Carolina | University of Minnesota | University of California—San Francisco | University of Michigan—Ann Arbor | EuroSciCon Conferences | University of Texas—Austin | Ohio State University | University of Illinois—Chicago | University of Kentucky | Purdue University | University of Florida | University of Maryland—Baltimore | University of Pittsburgh | University of Southern California | University of Washington | University of Wisconsin—Madison | University of Arizona | University of Iowa | University of Tennessee Health Science Center | University of Utah | University of Kansas | Virginia Commonwealth University | University at Buffalo | University of Colorado—Denver | Auburn University | University of California—San Diego | University of Oklahoma | Northeastern University | University of Cincinnati
Kingston University | Anglia Ruskin University | Aston University School of Life and Health Sciences | University of Birmingham | University of Brighton | Cardiff University | University of Huddersfield Chemical Sciences | University of Huddersfield Pharmacy | Liverpool John Moores University School of Pharmacy and Biomolecular Sciences | London Metropolitan University | Loughborough University | Newcastle University Northern Institute for Cancer Research | EuroSciCon | Nottingham Trent University School of Science and Technology | University of Nottingham School of Pharmacy | University of Strathclyde | University of Copenhagen | University of South Wales | University of Bradford | European University Cyprus | University of Groningen | University of Central Lancashire | University of Debrecen | Tu Braunschweig University | Marburg University | EuroSciCon Conferences | Greifswald University | Frankfurt University | Freiburg University | Kiel University | Wurzburg University | Fu Berlin University | Lomonosov Moscow State University | Saint-Petersburg State University | Novosibirsk State University
University of Tokyo | National University of Singapore | EuroSciCon | Kyoto University | University of Hong Kong | Peking University | Seoul National University | National Taiwan University | Osaka University | Tsinghua University | Chinese University of Hong Kong | Fudan University | The Hong Kong University of Science and Technology | Taipei Medical University | Mahidol University | Korea Advanced Institute of Science and Technology | Yonsei University | Shanghai Jiao Tong University | Nanyang Technological University | Chulalongkorn University | Tohoku University | Tokyo Medical and Dental University | Kyushu University | Nagoya University | Hokkaido University | Sungkyunkwan University | University of Science and Technology of China | Pohang University of Science and Technology | Korea University | University Malaya | Indian Institute of Science
Batna 2 University | University of Kinshasa | University of Lubumbashi | Ahram Canadian University | Alexandria University | British University in Egypt | Cairo University | German University in Cairo | Helwan University | Kafrelsheikh University | Mansoura University | Nahda University | Pharos University in Alexandria | EuroSciCon | Suez Canal University | Tanta University | Zagazig University | Addis Ababa University | Wollega University | Kwame Nkrumah University of Science and Technology | Kenya Methodist University | Kenyatta University | Elmergib University | University of Benghazi | University of Zawia | University of Misurata | University of Rwanda | Nelson Mandela Metropolitan University | North-West University | Rhodes University | EuroSciCon Conferences | University of KwaZulu | University of Limpopo | University of Pretoria | University of the Western Cape | University of the Witwaters | Ahfad University for Women | University of Khartoum | Omdurman Islamic University | Catholic University of Health and Allied Sciences | Kampala International University | Muhimbili University of Health and Allied Sciences | St. John's University of Tanzania | University of Monastir | Makerere University | Mbarara University of Science and Technology | University of Zambia | Harare Institute of Technology | University of Zimbabwe
12th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry February 26- 27, 2018 London, UK ; 14th International Conference and Exhibition on Nanomedicine and Pharmaceutical Nanotechnology April 09-11, 2018 Amsterdam, Netherlands; 11th European Biosimilars April 26-27, 2018 Rome, Italy ; 15th Annual European Pharma Congress May 07-09, 2018 Frankfurt, Germany ; International conference on Pharmaceutical Chemistry june 18-20, 2018 Dublin, Ireland ; 20th International Conference on Pharmaceutical Biotechnology December 07-09, 2017 Madrid, Spain ; 16th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems March 19-21, 2018 Berlin, Germany ; EuroSciCon ; 7th World Congress on Mass Spectrometry June 20-22, 2018 Rome, Italy ; 11th International Conference and Exhibition on Pharmacovigilance & Drug Safety June 21-22, 2018 London, UK ; 4th World Congress and Exhibition on Antibiotics and Antibiotic Resistance June 14-15, 2018 Barcelona, Spain ; 16th International Conference and Exhibition on Pharmaceutical Formulations July 26-27, 2018 Rome, Italy ; 4th International Conference and Expo on Drug Discovery, Designing & Development September 06-07, 2018 London, UK; 6th International Conference on Advanced Clinical Research and Clinical Trials September 10-11, 2018 Zurich, Switzerland; 8th World Congress on Chromatography September 13-14, 2018 Prague, Czech Republic; 18th Annual Pharmaceutical Chemical Analysis Congress November 05-06, 2018 Madrid, Spain ; EuroSciCon Conferences
5th International conference on Stress Diseases and Medicine October 24-25, 2018 Boston, USA; 2nd World Congress on Embryology and In Vitro Fertilization March 30-31, 2018 Orlando, USA; International Conference on Nano Medicine and Nanoparticles April 18-19, 2018 Las Vegas, USA ; 4th International Conference on Antibiotics: R&D, B2B April 20-21, 2018 Las Vegas, Nevada, USA ; International Conference & Exhibition on Biologics and Biosimilars March 26-27, 2018 Orlando, Florida, USA ; EuroSciCon Conferences ; Global Summit on Biopharma and Biotherapeutics May 14-15, 2018 Montreal, Canada ; Global Neuropharmacology and Neurochemistry Congress Los Angeles, CA, USA October 1-2, 2018 ; 5th International Conference on Natural Products & Marine Drugs June 04-05, 2018 Baltimore, Maryland, USA ; International Conference on Biobetters and Regulatory Implications June 27-28, 2018 Vancouver, Canada; EuroSciCon ; 34th International Conference on Pharmaceuticals and Nutraceuticals Oct 31- Nov 01, 2018 San Francisco; 13th International Conference on Biologics and Biosimilars October 24-25, 2018 Boston ; 13th International Conference on Biopharma and Biotherapeutics October 24-25, 2018 Boston, Massachusetts, USA; 12th World Drug Delivery Summit September 24-25, 2018 Chicago, Illinois, USA; 7th International Conference on Clinical Trials September 24-26, 2018 Chicago, USA ;15th International Conference on Pharmaceutical Formulations & Drug Delivery September 17-18, 2018 Philadelphia, Pennsylvania, USA.
2nd International Conference and Exhibition on Nanomedicine and Drug Delivery May 14-16, 2018 Tokyo, Japan; 2nd International Conference and Exhibition on Pharmaceutical Development and Technology May 14-15, 2018 Tokyo, Japan; Annual Pharmaceutical Biotechnology Congress May 17-19, 2018 Singapore ; 13th World Congress on Pharmacology and Toxicology May 24-25, 2018 Osaka, Japan; International conference on Pharmaceutics June 18-19, 2018 Tokyo, Japan; International Meeting On Nutraceuticals March 19-20, 2018 Singapore ; Global Experts Meeting On Clinical Research and Clinical Trials August 13-14, 2018 Tokyo, Japan ; 3rd Global Pharma Congress Oct 29-30, 2018 Osaka, Japan ; International Conference And Exhibition On Nanomedicine and Nanotechnology October 15-17, 2018 Tokyo, Japan ; 17th Annual Medicinal & Pharmaceutical Sciences Congress July 03-04, 2018 Bangkok, Thailand ; 5th International Conference on Pharmaceutical and Biomedical Engineering September 19-20, 2018 Singapore; EuroSciCon ;12th Global Ethnomedicine and Ethnopharmacology Conference August 20-21, 2018 Tokyo, Japan; International Conference on Biomedicine & Pharmacotherapy October 26-27, 2018 Osaka, Japan; 7th Global Advances in Mass Spectrometry September 17-18, 2018 Singapore; EuroSciCon Conferences ; 12th International Conference on Pharmacoepidemiology and Clinical Research October 17-18, 2018 Seoul, South Korea.
Mylan | Astellas Pharma | Novo Nordisk | Boehringer Ingelheim | Allergan | Takeda | Bristol-Myers Squibb | Eli Lilly | Teva Pharmaceutical Industries | Amgen | AbbVie | AstraZeneca | GlaxoSmithKline | Gilead Sciences | Merck | Sanofi | Roche | Pfizer | Novartis | Bayer | Johnson and Johnson | QPS | Biocrates | ThioMatrix | Polymun Scientific | EuroSciCon | Croma-Pharma | Affiris | Aposcience | EverCyte | Octapharma | Teleflex Medical | Janssen Pharmaceuticals | Lonza | Bone Therapeutics | Formac Pharmaceuticals | Oncurious | Sanofi Genzyme | Alexion | Baxter | Chemnovatic | CSL Behring | Custom Pharmaceuticals | EuroSciCon Conferences | Fujirebio Europe | Galen Limited | Martindale Pharma | Novo Nordisk A/S | Petrone Group | Purna Pharmaceuticals | Shire | UCB Pharma | Uni-Pharma | Covidien | Fresenius Se | Fresenius Medical | Rhoen Klinikum | Morphosys | Stada Arzneim | Carl Zeiss Meditec | Freudenberg medical | Emergent biosolutions | Aran biomedical | Norgine | Lexogen | Haplogen | Octimet Oncology | Anacura | Ablynx | Novasep | Flen Pharma | Toxikon | Zoetis | Pharmavize | Galapagos | Eurogentec | LinaTech | Stada | Synthon | Ferring Pharmaceuticals | Lonza | UBC | Leo Pharma | Saniona | DanDrit Biotechnology | Taconic Biosciences | West Pharma
Gilead Sciences | Johnson & Johnson | Pfizer | Abbott Laboratories | Bristol Myers Squibb | Amgen | Biogen Idec | Celgine Corporation | Merck & Co | Eli Lilly | Acura Pharmaceuticals | Alexion Pharmaceuticals | AMRI Global | Apricus Biosciences | BioCryst Pharmaceuticals | Biovista | Ceragenix Pharmaceuticals | Coherus BioSciences | Dynax pharmaceuticals | Endo International plc | Ensemble Therapeutics | Fabre-Kramer Pharmaceuticals | Genentech | H. K. Mulford Company | EuroSciCon | Impax Laboratories | Insys Therapeutics | Jones Pharma | KaloBios Pharmaceuticals | Lexicon Pharmaceuticals | Marathon Pharmaceuticals | Meyer Brothers Drug Company | NovaBay Pharmaceuticals | Nephroceuticals | Ovation Pharmaceuticals | Peregrine Pharmaceuticals | Pharmaceutical Research and Manufacturers of America | Proteon Therapeutics | Quark Pharmaceuticals | Reliant Pharmaceuticals | Sagent Pharmaceuticals | Sucampo Pharmaceuticals | Tonix Pharmaceuticals | EuroSciCon Conferences | Verus Pharmaceuticals
3-D Matrix | Agilent | BeiGene | BioDuro | China Biological Products | Fosun Pharma | Lumenis | MicroPort | Senju Pharmaceutical | Sihuan Pharmaceutical | Sinovac Biotech | DesigneRx Pharmaceuticals | Pharmadax | Denovo Biopharma | BioMarin Pharmaceuticals | Invitrogen | WuXi Apptec | AngioDynamics | SciGenom | Dishman Specialty Chemicals | Intas Pharmaceuticals | Zydus Cadila | Advinus Therapeutics | Sigma-Aldrich | Par Pharmaceutical | Gland Pharma | Natco Pharma | EuroSciCon | Haffkine Biopharmaceuticals | Allergan | Taisho Pharmaceutical | Dainippon Sumitomo | Wakunaga Pharmaceutical | Dainippon Sumitomo | Santen | Chugai Pharma | Kissei Pharmaceutical | WaVe Life Sciences | Mitsubishi Tanabe Pharma | Astellas | Daiichi Sankyo | AnGes | Kubota Pharmaceutical | Ohara Pharmaceutical | Daewon Pharma | Charles River Laboratories | EuroSciCon Conferences | Oxonc Development | Yungjin Pharmaceutical | Neopeutics | Austrianova Biotechnology | 3M | Clinuvel Pharmaceuticals | Micropoint Technologies | Sphaera Pharma | VolitionRx | China Chemical and Pharmaceutical Company | Foresee Pharmaceuticals
Fresenius Kabi Distribution | Luced Agencies | Akacia Health | Roche Pharmaceuticals | Biotech Laboratories | Allied Drug Company | Janssen-cilag | Teva Pharmaceuticals | Medimoc Sarl | Bayer International Service | Boehringer Ingelheim | Columbia Pharmaceuticals | Ultimate Sport Nutrition | Astra Zeneca Pharmaceuticals | Resmed Pharmaceuticals | Servier Laboratories | Embassy Pharmaceuticals | Amalgamated Pharmaceuticals | New S Buys | Afrox Limited | EuroSciCon Conferences | Amka Pharmaceuticals | EuroSciCon | Astra Pharmaceuticals | Brunel Laboratoria | Dia-Kure Ltd | Eden Pharmaceuticals Prod | Geo Schwulst Laboratories | GM Pharmaceuticals | Hersol Manufacturing Laboratories | Intramed | Johnson & Johnson | Kyron Laboratories | Merck Generics RSA | Novo Nordisk | Pharma Natura | Pharmacare Ltd | Resmed Pharmaceuticals | S N Pharmaceuticals | Smith & Nephew Pharmaceuticals | Smithkline Beecham
Journal of Pharmaceutical Sciences | International Journal of Pharmaceutics | The Pharmaceutical Journal | Pharmaceutical Research | European Journal of Pharmaceutics and Biopharmaceutics | Molecular Pharmaceutics | European Journal of Pharmaceutical Sciences | Asian Journal of Pharmaceutics | Journal of Pharmacy and Pharmacology | Indian Journal of Pharmaceutical Sciences | Journal of Pharmacy and Pharmaceutical Sciences | Drug Development and Industrial Pharmacy | Journal of Pharmacy Practice | American Journal of Pharmaceutical Education | International Journal of Drug Development & Research | EuroSciCon | Journal of Bioequivalence & Bioavailability | Journal of Bioanalysis & Biomedicine | Journal of Pharmacogenomics & Pharmacoproteomics | Journal of Vaccines & Vaccination | Journal of Drug Metabolism & Toxicology | Drug Designing: Open Access | Medicinal & Aromatic Plants | Journal of Biomolecular Research & Therapeutics | Research & Reviews in Pharmacy and Pharmaceutical Sciences | EuroSciCon Conferences | Journal of Molecular Pharmaceutics & Organic Process Research | Journal of Developing Drugs | Journal of Pharmaceutics & Drug Delivery Research | Molecular Enzymology and Drug Targets | Research & Reviews: Journal of Pharmaceutics and Nanotechnology | Journal of Pharmacokinetics & Experimental Therapeutics
Royal Pharmaceutical Society | International Pharmaceutical Federation | International Pharmaceutical Students' Federation | European Association of Employed Community Pharmacists in Europe | European Pharmaceutical Union | Pharmaceutical Group of the European Union | Pharmaceutical Society of Australia | The Pharmacy Guild of Australia | The Society of Hospital Pharmacists of Australia | Canadian Pharmacists Association | Chinese Pharmaceutical Association | Danish Association of Pharmaconomists | Indian Pharmacist Association | Pharmaceutical Society of Ireland | Kuwait Pharmaceutical Association | Pharmaceutical Society Of New Zealand | Norwegian Pharmacy Association | National Pharmacy Association | EuroSciCon | American Association of Colleges of Pharmacy | American Pharmacists Association | American Society for Pharmacy Law | American Society of Consultant Pharmacists | American Society of Health-System Pharmacists | Professional Compounding Centers of America | American College of Clinical Pharmacy | Canadian Society of Hospital Pharmacists | Pharmaceutical Association of Mauritius | Pakistan Pharmacists Association | EuroSciCon Conferences | Philippine Pharmacists Association | College of Psychiatric and Neurologic Pharmacists
Research Associate & Research Scientist - FR&D in Trikona Pharmaceuticals Private Limited | Pharmacist - Pentagon Global Solutions Limited | QA/QC in MSN Laboratories | Sr. Executive/asst. Manager/manager-Pharma Techni in Arihant Innochem Pvt Ltd | Sr. Executive / Exe IPR Formulation- Leading Pharma in Harman Finochem Ltd | Apotex- Analytical R&D Opportunity | Junior Research Fellow in South India Textile Research Association | Research & Development (F&D) in Zim Laboratories Limited | Sr Research Associate Formulations R&D in Celon Laboratories Ltd | Sr. Officer F & D (Pharmaceutics) in SMVA Consultants | Manager in Torrel Cos. Pvt. Ltd | EuroSciCon | Quality Assurance in Suven Life Sciences Ltd | Risk Management Plan Manager in Novartis | EuroSciCon Conferences | Associate Global Trial Director in Novartis | Product Manager - Ophthalmology | Cardio-Diabetes for Pharma company | Brand Manager / Product Executive in Senses pharmaceuticals ltd | Stores Clerk in Aristo Pharmaceuticals Pvt. Ltd. | Area Sales Manager in East West Pharma (Pvt) Ltd
Nasal sprays | Transdermal patches | Analytical nebulizer | Infusion pump | Jet injector | Bifurcated needle | Cypher stent | Dry-powder inhaler | Drug-eluting stent | Elixir | Epinephrine autoinjector | HumaPen | Mouthwash | Nanoneedle | Ommaya reservoir | Phonophoresis | Pill splitting | Rebiject II | Relative analgesia machine | Vesosome | Zydis
17th Edition of International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, October 04-06, 2018, Moscow, Russia
Dear Colleagues, Partners, Scientists, Bioengineers and Biodesigners, and Friends,
It is our genuine pleasure to invite you to attend 17th Edition of International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems planned to be held in Moscow, Russia, on October 04-06, 2018.
This event features lots of opportunities to network with partners from the entire World in an exciting environment whilst sensing an explosive burst in Translational Research & Applications to get Biopharma promoted, wishing to make innovative and upgraded strategic alliances to secure the latter and tasting a smell of fantastic Russian mentality and even soul to make unique bricks to construct business and friendly bridges to move ahead together!
The Conference will provide the ideal forum to stimulate ideas and establish collaborations as well as to initiate intense discussions to secure projects of the newest generations and to feature a highly interactive, stimulating and multidisciplinary Program including workshops, plenary sessions and panel discussions. Focus will be given to medical biotechnology, biopharmaceutical manufacturing, cell-based therapy, molecular diagnostics, imaging, microarray technology, biomarkers, targets and targeting, pharmaceutical biotechnology, protein engineering.
The Conference is thus becoming a significant event in the World of Biodesign and Bioengineering to be located in Moscow and bringing together professionals from the academic, healthcare and biopharma communities to enhance professional knowledge, gain new insights and exchange expertise. Through this meeting, we have not only presented outcomes of the fields, but also provided unique opportunities for constructive discussions among regulators, academia and industries on timely topics, in which we have formed a better understanding of the issues and ideas for solutions to those issues. Along with aforementioned, the Conference will provide a unique opportunity for Biopharma to exhibit their new products and to contact with the cardiologists more closely. And our mission can only be accomplished with close cooperation with various stakeholders such as government bodies, regulatory agencies and academia to secure stakeholders’ understanding and continued support to the activities toward the realization of our common goal. So, we hope that the deliberations and recommendations of this Conference will have a significant impact on the future directions of Biopharma business development, partnering trends, product opportunities, business models and strategies, licensing merger and acquisitions, outsourcing, venture capital and financing and intellectual property.
In this sense, let us as the Russian Ambassadors involved into aforementioned ask you to submit your latest research results and outcome of your experience for presentation. Together, we will become a stronger voice and global force with the ultimate goal of succeeding in securing the world with the best diagnostic and therapeutic tools to cure.
We hope that, despite the intense Program, you will be able to get some glimpses of the titanic Moscow which would unite Ancient History, Culture & Science, Adoration and Magic Images, and Promising Future. We do hope that you will enjoy the Conference and that your interaction with your colleagues will stimulate a creative exchange of ideas and will be personally rewarding!
Center for Personalized Medicine, Sechenov Univercity, and Dept for Translational Medicine, Moscow Engineering Physical Institute (MEPhI), Russia
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, and Moscow Engineering Physical Institute (MEPhI), Russia
Federal Almazov Medical Research Centre and St. Petersburg State Chemical Pharmaceutical Academy, St. Petersburg, Russia